RTSN news

Latest 1 stories · newest Nov 18, 2026

RTSN
Retension completes upsized IPO for hypertension drug RTN-001

Retension Pharmaceuticals raised $45.1 million net through an upsized IPO in October 2026 to fund clinical trials. Stock began trading on Nasdaq under the symbol RTSN on October 9.

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same RTSN feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/RTSN/newsSTART FREE